DMF, an incompletely understood immunomodulatory drug used to treat psoriasis and MS, was recently shown to produce anti‐inflammatory effects through inhibition of GAPDH and aerobic glycolysis, providing proof of concept that targeting glycolysis is a viable strategy for treating human disease. The gene discussed is GAPDH; the disease is psoriasis.